Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers

Key Points

• The aim is to identify genetic and clinical factors affecting voriconazole pharmacokinetics and hepatotoxicity risk.
• Analyzed the pharmacokinetics of voriconazole in CYP2C19 normal and intermediate metabolizers.
• Considered various genetic and clinical predictors for optimizing dosing.
• Emphasized the importance of therapeutic drug monitoring.
• Interindividual variability in voriconazole exposure was noted among metabolizer groups.
• Integrating genetics with therapeutic monitoring may help reduce the risk of hepatotoxicity.